Core Viewpoint - BillionToOne, Inc. has reiterated its full year 2025 revenue guidance of $293 million to $299 million and has initiated its full year 2026 guidance, projecting total revenue of $415 million to $430 million, indicating a growth of 40% to 45% compared to the midpoint of the 2025 guidance [1][4]. Group 1: Financial Guidance - The company expects full year 2026 revenue to be between $415 million and $430 million [4]. - This represents a growth of 40% to 45% compared to the midpoint of the full year 2025 guidance range [4]. - The company anticipates positive GAAP operating income for the full year 2026 [4]. Group 2: Company Overview - BillionToOne is a molecular diagnostics company headquartered in Menlo Park, California, focused on creating powerful and accurate tests that are accessible to all [2]. - The company utilizes a patented Quantitative Counting Templates™ (QCT™) molecular counting platform, which is the only multiplex technology capable of accurately counting DNA molecules at the single-molecule level [2]. Group 3: Leadership Perspective - Dr. Oguzhan Atay, Co-founder and CEO, expressed excitement about the opportunity to scale the company's differentiated platform and emphasized a clear roadmap to address significant clinical challenges [2].

Core Viewpoint - BillionToOne, Inc. is set to participate in the 44th Annual J.P. Morgan Healthcare Conference, highlighting its commitment to advancing molecular diagnostics [1] Company Overview - BillionToOne is headquartered in Menlo Park, California, and focuses on creating accessible and accurate molecular diagnostic tests [3] - The company utilizes a patented technology called Quantitative Counting Templates™ (QCT™), which is the only multiplex technology capable of counting DNA molecules at the single-molecule level [3]

Core Viewpoint - BillionToOne, Inc. reported strong financial results for Q3 2025, highlighting significant growth in revenue driven by its innovative molecular diagnostics technology, particularly in prenatal and oncology testing [3][5]. Financial Performance - Total revenue for Q3 2025 was $83.5 million, a 117% increase from $38.4 million in Q3 2024 [5][7]. - Prenatal clinical testing revenue reached $74.1 million, up 102% year-over-year, while oncology clinical testing revenue surged to $8.7 million, reflecting a 664% increase [5][7]. - Gross margin improved to 70% in Q3 2025 from 53% in Q3 2024, driven by higher average selling prices (ASP) and reduced costs per test [5][8]. - Operating income was $9.6 million in Q3 2025, compared to an operating loss of $12.6 million in Q3 2024 [9]. Test Volume and ASP - The company accessioned 162,900 tests in Q3 2025, a 51% increase from 107,900 tests in Q3 2024 [4][5]. - The overall ASP increased by 44% to $501 in Q3 2025 compared to $348 in Q3 2024 [6][7]. Cash Flow and IPO - Positive cash flow of $6.2 million was reported in Q3 2025 [5]. - The company raised gross proceeds of $314.0 million from its initial public offering (IPO) [10]. Future Guidance - BillionToOne expects full-year 2025 revenue to be between $293 million and $299 million, indicating growth of 92% to 96% compared to 2024 [11]. - The anticipated revenue for Q4 2025 is projected to be between $84 million and $90 million, representing an 86% to 100% increase year-over-year [11].

Core Viewpoint - BillionToOne, Inc. is set to release its financial results for the third quarter ending September 30, 2025, on December 9, 2025, after market close [1] Group 1: Financial Results Announcement - The financial results will be discussed in a conference call scheduled for 1:30 PM Pacific Time / 4:30 PM Eastern Time on the same day [1] - A live and archived webcast of the conference call will be available on the company's investor relations website [2] Group 2: Company Overview - BillionToOne is headquartered in Menlo Park, California, and focuses on molecular diagnostics [3] - The company aims to create powerful and accurate tests that are accessible to all [3] - BillionToOne's patented Quantitative Counting Templates™ (QCT™) platform is the only multiplex technology capable of accurately counting DNA molecules at the single-molecule level [3]

Core Points - BillionToOne, Inc. successfully closed its upsized initial public offering (IPO) of 5,233,765 shares of Class A common stock at a public offering price of $60.00 per share, resulting in gross proceeds of approximately $314.0 million before deductions [1] - The IPO included the full exercise of the underwriters' option to purchase an additional 682,665 shares [1] - The company's Class A common stock began trading on the Nasdaq Global Select Market under the ticker symbol "BLLN" on November 6, 2025 [1] Company Overview - BillionToOne is a molecular diagnostics company headquartered in Menlo Park, California, focused on creating powerful and accurate tests that are accessible to all [4] - The company utilizes a patented technology called Quantitative Counting Templates™ (QCT™), which is the only multiplex technology capable of accurately counting DNA molecules at the single-molecule level [4] Offering Details - The registration statement related to the securities was filed with the U.S. Securities and Exchange Commission and became effective on November 5, 2025 [2] - A prospectus describing the terms of the offering has been filed with the SEC and is available on their website [2]

Core Points - BillionToOne, Inc. has announced the pricing of its upsized initial public offering (IPO) of 4,551,100 shares at a price of $60.00 per share, with gross proceeds expected to be approximately $273.1 million [1] - The IPO is set to begin trading on the Nasdaq Global Select Market under the ticker symbol "BLLN" on November 6, 2025, and is expected to close on November 7, 2025, subject to customary closing conditions [1] - The underwriters have a 30-day option to purchase an additional 682,665 shares at the initial public offering price [1] Company Overview - BillionToOne is a molecular diagnostics company headquartered in Menlo Park, California, focused on creating powerful and accurate tests that are accessible to all [5] - The company utilizes a patented technology called Quantitative Counting Templates™ (QCT™), which is the only multiplex technology capable of accurately counting DNA molecules at the single-molecule level [5] Underwriters - The joint book-running managers for the offering include J.P. Morgan, Piper Sandler, Jefferies, and William Blair, with Stifel, Wells Fargo Securities, and BTIG also acting as book-running managers [2]

Core Viewpoint - BillionToOne, Inc. has launched a roadshow for its proposed initial public offering (IPO) of 3,846,000 shares of Class A common stock, with an expected price range of $49.00 to $55.00 per share [1]. Company Overview - BillionToOne is a molecular diagnostics company based in Menlo Park, California, focused on creating powerful and accurate tests that are accessible to all [4]. - The company utilizes a patented technology called Quantitative Counting Templates™ (QCT™), which is the only multiplex technology capable of accurately counting DNA molecules at the single-molecule level [4]. IPO Details - The proposed IPO includes a 30-day option for underwriters to purchase an additional 576,900 shares at the initial offering price, excluding underwriting discounts and commissions [1]. - The company has applied to list its Class A common stock on the Nasdaq Global Select Market under the ticker symbol "BLLN" [1]. - J.P. Morgan, Piper Sandler, Jefferies, and William Blair are acting as joint book-running managers for the offering, with Stifel, Wells Fargo Securities, and BTIG also participating as book-running managers [1].